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Abstract
Natural killer (NK) cells play an important role in the detection and elimination of tumors and virus-infected cells by the
innate immune system. Human NK cells use cell surface receptors (KIR) for class I MHC to sense alterations of class I on
potential target cells. Individual NK cells only express a subset of the available KIR genes, generating specialized NK cells that
can specifically detect alteration of a particular class I molecule or group of molecules. The probabilistic behavior of human
KIR bi-directional promoters is proposed to control the frequency of expression of these variegated genes. Analysis of a
panel of donors has revealed the presence of several functionally relevant promoter polymorphisms clustered mainly in the
inhibitory KIR family members, especially the KIR3DL1 alleles. We demonstrate for the first time that promoter
polymorphisms affecting the strength of competing sense and antisense promoters largely explain the differential
frequency of expression of KIR3DL1 allotypes on NK cells. KIR3DL1/S1 subtypes have distinct biological activity and coding
region variants of the KIR3DL1/S1 gene strongly influence pathogenesis of HIV/AIDS and other human diseases. We propose
that the polymorphisms shown in this study to regulate the frequency of KIR3DL1/S1 subtype expression on NK cells
contribute substantially to the phenotypic variation across allotypes with respect to disease resistance.
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Introduction
Natural killer (NK) cells play an important role in the detection
and elimination of tumors and virus-infected cells by the innate
immune system [1]. NK cells can identify stressed cells via cell
surface receptors for class I MHC that sense alterations of these
molecules on potential target cells [2]. Human NK cells express
inhibitory receptors of the Killer cell Immunoglobulin-like
Receptor family (KIR) that recognize HLA class I molecules
[3,4], whereas mouse NK cells use members of a lectin–related
family (Ly49) to recognize mouse class I MHC [5]. Both gene
families contain activating counterparts; however, the ligands of
these activating receptors are not well characterized [6,7].
Activating KIR lack the immunotyrosine inhibitory motif (ITIM)
present in the intracellular domain of inhibitory KIR due to a
carboxy-terminal truncation of the protein, and have thus been
named as short forms of the receptors. For example, KIR3DS1 is
an activating receptor highly related to the KIR3DL1 (long form)
inhibitory receptor (http://www.ebi.ac.uk/ipd/kir/align.html).
The KIR genes are located on chromosome 19 in a head to tail
cluster with approximately 2 kb separating the polyadenylation
signal of one gene from the translation initiation codon of the next.
The numberof genes present in KIRhaplotypes is variable, however
four genes (KIR3DL3, KIR3DP1, KIR2DL4, KIR3DL2) are present
on virtually all haplotypes, and are thus considered as framework
genes. Two major classes of KIR haplotypes have been identified.
The A haplotype contains four genes in addition to the framework
genes (KIR2DL1, KIR2DL3, KIR3DL1, KIR2DS4), representing a
predominately inhibitory haplotype. There are many B haplotypes,
containing various combinations of the activating KIR genes. The A
haplotype and a representative B haplotype are shown in Figure 1.
Individual NK cells only express a subset of the available class I
MHC receptors, presumably to generate specialized NK cells that
can specifically detect alteration of a particular class I molecule or
group of molecules [8–10]. The variegated expression of class I
MHC receptors, KIR and Ly49, by NK cells is a unique case of
selective transcriptional activation of a subset of genes present
within a cluster. The B cell, T cell, and olfactory receptors are
examples whereby a single receptor is selected from a large
repertoire, and only one type of receptor is expressed per cell
[11,12]. In contrast, several KIR or Ly49 genes can be expressed by
a single NK cell in a stochastic manner [9,10].
A considerable amount of information relating to the mecha-
nisms controlling expression of the class I receptor genes has been
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human and mouse systems have emerged. Expression is controlled
by a stochastic mechanism; the probability of co-expression of two
distinct inhibitory receptors is equal to the product of their
individual frequencies, and NK cells appear to turn on class I
MHC receptors until a self-reactive inhibitory receptor is present
[13,14]. Active receptor genes are hypo-methylated and silent genes
aremethylated [15–18].Multiplepromotersarepresentwithineach
gene in both the KIR and Ly49 clusters, including bi-directional
promoters that are predicted to function as probabilistic switches
controlling the probability of gene activation [19–22].
There is a high degree of polymorphism in the KIR gene family,
including differences in haplotypic gene content among individuals
[23]. Allelic variation has been observed for most KIR genes;
however functional polymorphism within the promoter region of
KIR genes has only been reported for KIR2DL5 alleles, where loss
of an AML-binding site was associated with the lack of KIR2DL5
transcription [24]. Allelic variation in the KIR3DL1 promoter has
been reported [16]; however the functional consequences were not
investigated.
A large number of KIR3DL1 alleles have been identified,
including an activating allele, KIR3DS1, making the KIR3DL1/S1
locus unique within the cluster (http://www.ebi.ac.uk/ipd/kir/
align.html). Numerous studies have demonstrated the effect of
KIR3DL1 protein polymorphisms on the level of cell surface
expression and the HLA recognition properties of the receptors
[25–29]. There are currently at least four distinct categories of
mean channel fluorescence intensity (MFI) of KIR3DL1 on the
NK cell surface as detected by the DX9 and Z27 mAbs: low
(KIR3DL1*028, *053), intermediate (KIR3DL1*005, *006, *007),
high (KIR3DL1*001, *002, *003, *008, *015, *020) and null
(KIR3DL1*004) [25–27,30]. The distinct MFIs observed were
attributed to differences in the level of cell surface expression
rather than altered antibody-binding affinity. Although KIR3DL1
is known to bind multiple HLA allotypes that possess the Bw4
public serological epitope defined by residues 77–83 of the HLA
a1 domain, the degree to which KIR3DL1 binds individual HLA-
A and B alleles is variable among the different KIR3DL1 allotypes
[28,29]. Division of allelic groupings based on these differential
characteristics of KIR3DL1/S1 molecules has associated strongly
with HIV disease outcomes in genetic studies [31,32].
The genetically-linked variability of the frequency of NK cells
that express KIR3DL1 was established over 10 years ago [33], but
the molecular basis of this variation has never been defined. The
recent identification of bi-directional promoters in the KIR genes
indicates that the relative strength of competing sense and
antisense promoters may determine the probability of gene
expression, similar to the model proposed for the control of Ly49
gene expression by the Pro1 probabilistic switch [19,20,22]. To
test this hypothesis, promoter polymorphisms that affect promoter
activity were identified, and the frequency of receptor expression
associated with individual alleles was determined. The availability
of a monoclonal antibody (DX9) [34] that specifically recognizes
KIR3DL1 and not KIR3DS1 provided the opportunity to
specifically measure the frequency of expression of a single
KIR3DL1 allele in heterozygous KIR3DL1/KIR3DS1 individuals
and correlate the frequency of expression with specific promoter
polymorphisms. The results reveal for the first time that specific
KIR3DL1 promoter polymorphisms affect the frequency of
expression, which has consequences in terms of NK cell function
in disease resistance.
Results
Identification of KIR Promoter Polymorphisms
Three KIR genes were chosen for a detailed analysis of allelic
variation in the promoter region based on the availability of
specific antibodies to study their expression: KIR3DL1 (detected by
DX9 and Z27 mAbs); KIR2DS4 (detected by FES172 mAb);
KIR2DL3 (detected by ECM41 mAb). Promoter polymorphisms
were identified by sequencing PCR-generated clones of the core
promoter region from individual donors, as well as analysis of KIR
genomic sequences deposited in GenBank. Figure 2A shows the
promoter polymorphisms observed in the donor population for the
KIR3DL1/S1 and KIR2DS4 genes as well as KIR2DL5 polymor-
phisms identified in GenBank. The most frequently observed
promoter sequence is shared by the KIR3DL1*002, -*007,- *008,
-*015 and -*020 alleles (shown as the reference promoter
sequence), and single nucleotide polymorphisms (SNPs) are shown
for other KIR3DL1 alleles as well as the KIR2DS4 and KIR2DL5
alleles. The KIR2DL1 and KIR2DL3 genes are shown as examples
of KIR promoters that were not found to be polymorphic in the
donor population. KIR genotyping identified 73 individuals in the
NCI-Frederick donor population possessing at least one copy of
the KIR2DL3 gene; however, all of the KIR2DL3 promoter
sequences were identical. The KIR3DL1*004 promoter is identical
3DL3 2DL3 2DP1 2DL1 3DP1 3DL1 2DL4 2DS4 3DL2
A haplotype
3DL3 2DL2 3DP1 3DS1 2DL4 2DS4 3DL2 2DS2
B haplotype
2DS1 2DS5 2DL5
Figure 1. Organization of the KIR gene cluster. The KIR gene order
is shown for the A haplotype and a representative B haplotype.
Inhibitory KIR genes are shown as red boxes, whereas the activating
genes are shown in green. The framework genes are indicated by grey
boxes, and pseudogenes are indicated by black boxes. Each gene spans
between 10–16 kb, and the intergenic distances are approximately 2 kb
with the exception of the 14 kb region upstream of the KIR2DL4 gene.
doi:10.1371/journal.pgen.1000254.g001
Author Summary
Natural killer (NK) cells represent a specialized blood cell
that plays an important role in the detection of virus-
infected or cancer cells. NK cells recognize and kill diseased
cells using receptors for self antigens (HLA) that are
frequently altered on aberrant cells. The HLA receptors are
known as Killer cell Immunoglobulin-like Receptors, or KIR.
Humans possess from four to 14 KIR receptor genes in
their genome, and individual NK cells express a subset of
the available KIR genes, generating specialized NK cells
that detect alterations in specific HLA proteins. The
mechanism of this unusual selective gene activation was
recently shown by our group to be controlled by a
probabilistic bi-directional promoter switch that turns on a
given gene at a pre-determined frequency in the NK cell
population. The current study shows that the properties of
the switches in terms of the relative activity of forward (on)
versus reverse (off) promoter activity is directly correlated
with the frequency at which a given gene is expressed
within the NK cell population. These results have
important implications for our understanding of the role
of NK cells in viral resistance and bone marrow transplants.
Genetic Control of KIR Expression Frequency
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role for the KIR3DL1*004 allele, since the KIR protein produced
by this allele is not expressed on the NK cell surface [26]. The
KIR3DL1/S1 alleles possess SNPs in the YY1, E2F, and Sp1
transcription factor binding sites, predicting functional differences
in promoter activity of these alleles. On the other hand, the SNPs
present in the KIR2DS4 alleles and the KIR2DL3 promoter are not
associated with any predicted transcription factor binding sites,
suggesting that the promoter alleles of these genes should have a
similar level of activity.
Distinct Bi-Directional Promoter Activity of Individual
KIR3DL1 Alleles
Previous studies have shown that the presence of ligand or
competition from other KIR receptor-ligand pairs can influence
the percentage of NK cells expressing a given KIR [14,27,35].
However, we have proposed that the primary determinant of the
frequency of KIR gene activation is related to the probability of
sense or antisense transcription from the proximal promoter
[20,22]. This model of probabilistic KIR expression predicts that
there should be differences in the relative sense and antisense
activities of individual KIR proximal promoter alleles to explain
the observed differences in the percentage of NK cells that express
different alleles of a given KIR gene. We previously observed that
the KIR3DL1*001 and KIR3DL1*002 alleles have distinct bi-
directional promoter characteristics [22]. To examine the effect of
sequence differences observed in all of the KIR3DL1/S1 promoter
alleles, DNA fragments containing the previously identified core
bi-directional promoter region (2229 to 21) [22] of the
KIR3DL1*001, KIR3DL1*002, KIR3DL1*005, and KIR3DS1 genes
were cloned into the pGL3 vector in both orientations and the
forward and reverse promoter activities were determined in
transfected YT-Indy human NK cells. As shown in Figure 2B, the
forward and reverse promoter activities of the individual KIR3DL1
promoter alleles are distinct. Since the ratio of forward to reverse
promoter activities should determine the probability of forward
transcription and gene activation, the ratio is shown for each allele
(Figure 2B). The KIR3DL1*001 promoter had the highest ratio of
forward to reverse promoter activity and KIR3DL1*002 had the
lowest, predicting that these two alleles should have the highest
and lowest frequency of expression respectively. The transcrip-
tional activities of the KIR3DL1*001 and KIR3DS1 promoters in
the forward direction are higher than those of the KIR3DL1*002
and KIR3DL1*005 promoters. The Sp1 site is disrupted (GRA) in
the KIR3DS1, KIR3DL1*001 and KIR3DL1*005 alleles (Figure 2A);
however, an increase in the strength of the forward promoter is not
seen in the KIR3DL1*005 promoter, suggesting that the additional
polymorphism within the E2F site at position 265 unique to the
KIR3DL1*005 promoter (ARG) counteracts the positive effect of
the SNP in the Sp1 site. A recent report has demonstrated that this
polymorphism reduces E2F binding, resulting in reduced forward
promoter activity [36]. The forward promoter activity of the
KIR3DS1 promoter was highest of the four tested, including that of
the KIR3DL1*001 allele. There is an additional SNP in the YY1
site of the KIR3DS1 promoter (TRC), and the YY1 site has been
shown to inhibit forward and reverse promoter activities [22,37].
Therefore, the increased forward and reverse activities of KIR3DS1
relative to KIR3DL1*001 is likely due to a disruptive effect of the
additional SNP in the YY1 site unique to the KIR3DS1 promoter.
Distinct Bi-Directional Promoter Activity of Individual
KIR2DL5 Alleles
Our previous characterization of the KIR2DL5*001 promoter
indicated that disruption of the YY1 site resulted in a bidirectional
element with dominant reverse promoter activity [22]. Examina-
tion of the KIR2DL5*003 promoter revealed the presence of an
additional polymorphism in the Sp1 site. Figure 2C compares the
promoter activity of KIR2DL5*003 to the *001 and *002 alleles.
The disruption of the AML-binding site in the non-transcribed
KIR2DL5*002 allele generates a promoter with weakened but
balanced forward and reverse activity as previously shown for the
KIR3DP1 promoter [22]. The novel polymorphism in the Sp1 site
of the KIR2DL5*003 promoter results in a further decrease in
forward promoter activity. A recent report by Estafania et al. [38]
has revealed that KIR2DL5 is expressed by only a small
percentage of NK cells (,5%), consistent with the dominant
reverse promoter activity observed with the promoters of the two
expressed alleles (*001 and *003). The reduced forward promoter
activity of KIR2DL5*003 suggests that it will be expressed on an
even lower percentage of NK cells than the KIR2DL5*001 gene.
Lack of Functional Polymorphisms in the KIR2DL3 and
KIR2DS4 Promoter Alleles
Although there were several promoter polymorphisms observed
within the KIR2DS4 genes, the SNPs observed were in regions
lacking known transcription factor binding sites (Figure 2A). The
promoter activities of the KIR2DS4 alleles and the KIR2DL3 gene
were determined, and there are only small differences in the
forward and reverse promoter activities of the KIR2DS4 alleles and
KIR2DL3 as predicted by the lack of SNPs in the known
transcription factor binding sites (Figure 2D).
Allelic Variation in KIR Promoter Activity Is Controlled by
Flanking YY1 and Sp1 Stes
With the exception of the non-transcribed KIR2DL5*002 allele
that has an altered AML-binding site [24] (the only KIR allele
known to have such a variant), the transcription factor binding
sites within the core bi-directional KIR promoters are conserved
between individual genes and alleles. Modulation of KIR bi-
directional promoter activity appears to be due to polymorphisms
in the YY1 and Sp1 sites that flank the core promoter region
(Figure 2). The Sp1 transcription factor binding site is downstream
of the major transcription start site of the KIR forward transcript
Figure 2. Impact of polymorphisms present in the KIR3DL1, KIR2DS4, KIR2DL3, and KIR2DL5 genes on promoter activity. (A) A schematic
of the KIR bi-directional promoter region is shown with the position of transcription factor binding sites indicated by labeled boxes. The sites of
transcript initiation for the sense and antisense promoters are shown by the rightward and leftward arrows respectively. The vertical lines indicate the
positions of polymorphic nucleotides relative to the KIR3DL1*002 allele. Numbers above the lines indicate the positions of the polymorphic residues
relative to the start codon of the KIR3DL1 gene. The nucleotide present at each variable position is shown for the KIR3DL1*002 gene and only
differences are shown for the remaining alleles. (B) The promoter activities of KIR3DL1/S1 promoter alleles are shown. The 229 bp core promoter
region of the KIR3DL1 alleles and KIR3DS1 were cloned into the pGL3 reporter vector in the forward and reverse orientation, and the promoter activity
of each construct was determined by transfection into the YT-Indy human NK cell line. The ratio of forward promoter activity to reverse activity (F/R
ratio) is listed for each allele. (C) Promoter activities of KIR2DL5 alleles. (D) Characterization of promoter activity of the KIR2DS4 alleles and the KIR2DL3
promoter. Values represent fold increase of luciferase activity relative to empty pGL3 vector. The mean and SD of at least 3 independent experiments
are shown.
doi:10.1371/journal.pgen.1000254.g002
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antisense transcription is initiated [22]. In vitro promoter assays
demonstrated that disruption of the YY1 site is associated with
increased promoter activity in the reverse orientation, whereas
polymorphisms in the Sp1 site are associated with increased
forward promoter activity [22]. These results indicate that Sp1
binding has an inhibitory effect on forward transcription whereas
YY1 binding attenuates antisense transcription. The
KIR3DL1*001 promoter has a SNP that disrupts the Sp1 site,
possesses high forward transcriptional activity and low reverse
activity. (Figure 2). The KIR2DL1 promoter has 3 SNPs, one in the
YY1 site, and two in the Sp1 site (Figure 2A). These changes result
in a promoter with high transcriptional activity in both directions
[22]. The KIR2DL5A*001 promoter has a single SNP that disrupts
the YY1 site, leading to dominant reverse promoter activity. The
additional Sp1 polymorphism present in the KIR2DL5*003 allele
further suppresses forward transcriptional activity (Figure 2C).
Taken together, these observations support a model where the
probability of transcription in the sense or antisense direction is
controlled by the flanking YY1 and Sp1 sites.
Since the analysis of several KIR promoters revealed a
significant effect of SNPs in the Sp1 site spanning nucleotides
224 to 233 relative to the start of translation, EMSA analysis of
this region was performed with oligonucleotide probes containing
the polymorphisms observed in the various promoter alleles as well
as unique Sp1 site polymorphisms found in the KIR2DS5 and
KIR3DL2 genes (Figure 3A). As shown in Figure 3B, polymor-
phisms associated with increased forward promoter activity
(KIR3DL1*001 GRA; KIR2DL1 GRT) had reduced or undetect-
able Sp1 binding. The Sp1 site of the KIR2DL5*003 allele bound
very strongly to Sp1, consistent with the decreased forward
promoter activity of this allele. These results are consistent with the
proposed modulation of forward promoter activity by Sp1 binding
downstream of the major forward transcription initiation site.
Quantitation of In Vivo KIR3DL1 Antisense Transcript
Levels
In order to confirm the predicted effect of the observed changes
in promoter activity associated with KIR3DL1 promoter polymor-
phisms, the in vivo levels of antisense transcript were measured by
quantitative PCR. Primers specific for KIR3DL1 or KIR3DS1
antisense transcripts were used, along with NKp46 coding region
primers to control for the percentage of NK cells present in
individual donor’s blood. Figure 4A shows the result of antisense
transcript quantitation in donors with KIR3DL1 alleles that have
either strong (KIR3DL1*002) or weak (KIR3DL1*001/*004)
antisense promoter activity based on the transfection data shown
in Figure 2B. There is a significant increase in the level of antisense
transcript detected when an allele with a strong antisense promoter
activity is present (KIR3DL1*002). The relationship between the
frequency of receptor expression and antisense transcript levels
was also studied (Figure 4B). A significant negative correlation was
found between antisense level and the frequency of NK cells
expressing a given allele, supporting the hypothesis that antisense
transcription blocks KIR gene activation.
Frequency of KIR Expression in Donors
Although the percentage of NK cells that express individual KIR
genes has been examined [27,35], no evidence for allele-based
differences in expression frequency based on promoter polymor-
phisms has ever been reported. In order to directly assess the
frequency of expression of individual KIR3DL1 alleles, donors
possessing a single copy of the allele of interest were studied. The
expression of a single KIR3DL1 allele was examined with the DX9
antibody, which specifically reacts with KIR3DL1 and not
KIR3DS1 in donors heterozygous for KIR3DL1 and KIR3DS1.
The Z27 monoclonal antibody, on the other hand, has weak
reactivity with KIR3DS1 in addition to KIR3DL1 [29,39,40];
therefore, Z27 was used to measure the frequency of NK cells
expressing KIR3DS1. Figure 5A shows the results obtained from
an analysis of KIR3DL1/KIR3DS1 heterozygous donors identified
by KIR typing of individuals in the NCI-Frederick Research
Donor Program. The KIR3DL1*001 allele is expressed by a
significantly higher proportion of NK cells than any other
KIR3DL1 allele, consistent with the high level of forward
transcriptional activity and low reverse activity observed for
KIR3DL1*001 (F/R ratio of 8.7; Figure 2B). The frequency of
expression of KIR3DS1 was analyzed in individuals that possessed
the KIR3DL1*004 allele on the opposite haplotype (Figure 5B),
since the KIR3DL1*004 allele is not expressed on the cell surface,
thus avoiding the detection of KIR3DL1 by the Z27 mAb that
reacts with both KIR3DL1 and KIR3DS1 [29,39,40]. A single
KIR3DS1 allele leads to the expression of KIR3DS1 on 30–50% of
the NK cell population. This high frequency of expression was
unexpected since the KIR3DS1 promoter possesses an intermediate
ratio of forward to reverse promoter activity (Figure 2B).
The lack of functional polymorphisms in the KIR2DL3 and
KIR2DS4 gene promoters suggests that the corresponding KIR
proteins should be expressed at similar frequencies on NK cell
populations. An analysis of KIR2DL3 and KIR2DS4 expression
using antibodies specific for each receptor showed that the
frequency of expression observed for KIR2DL3 (Figure 5D) is
similar to that of KIR3DL1*002 (Figure 5A), consistent with the
similar promoter characteristics of these two genes (Figure 2).
Remarkably, the frequency of expression of KIR2DS4 was very
high (mean=48%; Figure 4C), even though the KIR2DS4
promoter is also functionally equivalent to the KIR3DL1*002
promoter in the luciferase assay (Figure 2). This discrepancy may
be due to a difference in the post-expression selection of NK cells
expressing activating KIR. Along these same lines, it is also
possible that the high frequency of KIR3DS1 expression
(Figure 5B) may be due at least in part to post-expression selection.
Effect of Gene Dosage on Expression Frequency
The comparison of KIR2DL3 expression in individuals
possessing one copy of the KIR2DL3 gene (KIR2DL2/KIR2DL3
genotype) with individuals carrying two copies (KIR2DL3/
KIR2DL3 genotype) revealed a clear additive effect of gene dosage
on expression frequency (Figure 5D). The mean KIR2DL3
expression frequency in individuals with one copy of the gene
was 18%, whereas those individuals possessing two copies had a
mean expression frequency of 35%. This result is consistent with
the independent regulation of the two alleles. The expression
frequency of two alleles should equal the sum of the frequency of
expression of each allele minus the predicted frequency of cells
expressing both alleles. In the case of KIR2DL3, since each allele
should have the same probability of expression (p), the predicted
expression of two alleles is 2p-p
2 (.362.03) or 33%, in close
agreement with the observed frequency of 35%. The effect of two
copies of KIR2DS4 on expression frequency could not be
determined in this study since most donors possessing only the
KIR2DS4*001 allele had a KIR B haplotype on the other
chromosome and would not be expected to have two copies of
KIR2DS4*001. Like the gene dosage effect of KIR2DL3, KIR3DS1
expression frequency also appears to be additive based on gene
copy number. We had previously shown that individuals with two
copies of KIR3DS1 have a mean expression frequency of 61% [40]
consistent with the expected frequency of 62% (.762.14) predicted
Genetic Control of KIR Expression Frequency
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mean expression frequency of 38%.
Discussion
There are undoubtedly many factors that contribute to the
generation of the KIR repertoire, including the presence of ligands
and competition between inhibitory receptors. Reports by Shilling
et al. [33] and Yawata et al. [27] have shown clear effects of HLA
on the frequency of expression; however, both studies concluded
that the major factor controlling the degree of KIR expression was
somehow related to the KIR genotype, but the mechanism was not
resolved. The current study demonstrates for the first time that
SNPs in transcription factor binding sites, which can occur
Figure 3. Effect of KIR promoter polymorphisms on Sp1 binding. EMSA analysis of the Sp1 binding region corresponding to the
polymorphisms observed in KIR alleles. (A) Oligonucleotides used for EMSA. The sense strand of oligonucleotide probes corresponding to the
predicted Sp1-binding region of the indicated KIR genes is shown. The nucleotide residue labeled (226) corresponds to the same 226 position
shown in Figure 2A. (B) EMSA analysis performed on YT nuclear extracts with probes indicated in A. The right panel shows a supershift of the Sp1
consensus probe from YT extracts or in the presence of recombinant human Sp1 protein (rhSp1).
doi:10.1371/journal.pgen.1000254.g003
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functional activity of the bi-directional KIR promoters that are
associated with distinct frequencies of receptor expression.
A correlation between forward promoter activity and frequency
of gene expression was observed for the bi-directional Pro1
promoter in the murine Ly49 genes, since the reverse promoter
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Figure 4. Quantitative analysis of KIR3DL1/S1 antisense transcripts. (A) Comparison of relative antisense transcript levels in individuals
bearing alleles shown to have high (*002) or low (*001/*004) antisense promoter activity in vitro. (B) Correlation of relative antisense transcript levels
with frequency of NK cells expressing different KIR3DL1 allotypes. Symbols shown correspond to individuals possessing the KIR alleles as shown in A.
The KIR3DL1*004 allele was removed from the analysis since it is not expressed on the NK cell surface.
doi:10.1371/journal.pgen.1000254.g004
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transcription from the Pro1 promoter is required for activation of
the downstream Pro2 promoter that is responsible for Ly49
expression in mature NK cells, since deletion of Pro1 abrogates
Ly49 gene expression [41]. Although the probabilistic activation of
KIR expression is also associated with the balance between sense
and antisense transcription from a bi-directional promoter, the
mechanism of gene activation must be distinct from the murine
Ly49 system, since KIR expression in mature human NK cells
originates from a bi-directional proximal promoter that appears to
lose the ability to generate antisense transcripts in mature NK cells
[22]. Perhaps antisense KIR transcription in developing human
NK cells antagonizes the ability of sense transcripts from the
upstream distal KIR promoter to open the locus, either by direct
promoter competition or the production of double-stranded RNA
in the KIR proximal promoter region.
The variation in sense versus antisense promoter activity of the
Ly49 probabilistic promoter is controlled by competition between
overlapping C/EBP and TATA elements at either end of the bi-
directional element. In contrast, the core bi-directional KIR
promoter is conserved, and the variation in promoter strength
between genes and alleles is controlled by flanking YY1 and Sp1
sites. The ARG substitution present in the upstream YY1 site of
the KIR2DL1 and KIR2DL5 promoters has previously been shown
to abrogate YY1 binding [37], consistent with the observed
increase in reverse promoter activity associated with this SNP
shown herein. An additional SNP in the YY1 site is present in the
KIR3DS1 gene, and this change is associated with an even higher
level of forward promoter activity, but this is offset by an increased
level of reverse activity as well. The frequency of KIR3DS1
expression was significantly higher than KIR3DL1*001; however,
the analysis of the KIR2DS4 gene suggests that additional factors
Figure 5. Frequency of expression of KIR3DL1/S1, KIR2DS4 and KIR2DL3 on the NK cell population. (A) The percentage of NK cells
expressing KIR3DL1 in donors containing only one expressed inhibitory allele is indicated for individuals with a KIR3DS1/3DL1 genotype. (B) The
percentage of NK cells expressing either KIR3DS1 or the indicated KIR3DL1 allotypes was determined in individuals heterozygous for KIR3DS1 or
KIR3DL1 and the KIR3DL1*004 allele (*004 is not expressed on the NK cell surface). (C) The percentage of donor peripheral blood NK cells expressing
KIR2DS4 is shown. Individuals are grouped based on the presence of the expressed allele or the non-expressed KIR2DS4 alleles that possess a 22 bp
deletion (KIR2DS4-del) Heterozygous KIR2DS4*001/KIR2DS4-del donors possess one expressed KIR2DS4 allele, whereas KIR2DS4*001 (in the absence of
the null allele) individuals are expected to possess one copy of KIR2DS4 but could potentially contain a second KIR2DS4*001 allele. (D) Expression of
KIR2DL3 on peripheral blood NK cells is shown. Individuals typed as possessing KIR2DL3 virtually always have two copies of the gene, whereas donors
that have KIR2DL2/2DL3 are expected to have only a single copy of KIR2DL3.
doi:10.1371/journal.pgen.1000254.g005
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control the frequency of NK cells expressing activating receptors.
Although the in vitro transcriptional activities of the KIR2DS4
promoter alleles are similar to the KIR3DL1*002 allele that is
expressed on a low frequency of NK cells (,10%), KIR2DS4 is
expressed by 48% of NK cells on average. This discrepancy
suggests that the KIR2DS4 and possibly KIR3DS1 subsets of NK
cells undergo positive selection that increases the frequency of
receptor expression in the NK pool. In this respect, it is worth
noting that the mouse activating receptors Ly49D and Ly49H are
co-expressed at a higher frequency than predicted by the ‘‘product
rule’’, suggesting that their expression is not governed by stochastic
processes alone [42].
The current study provides the groundwork for further
investigation of the role of promoter polymorphisms in KIR gene
expression patterns. The identification and analysis of KIR
promoter polymorphisms in more diverse donor populations
together with the development of additional antibodies specific for
individual KIR gene products will provide a more complete picture
of the degree to which promoter polymorphisms modulate KIR
expression frequency. Nevertheless, the information provided in
this report is immediately applicable to studies of KIR locus
variation on human disease and may explain some of the previous
associations in this regard [43]. The quality of the NK response to
a given pathogen is very likely to depend on the frequency of NK
cells expressing the relevant KIR, which we have shown to be
dependent on the specific promoter sequence driving transcription
of the KIR allele/gene. KIR3DL1 allotypes that are expressed at a
high level on the NK cell surface [25] associate with delayed
progression to AIDS in HIV-infected individuals [31]. A high
frequency of expression of these allotypes across the NK cell
population would presumably lead to a larger population of
mature, functional NK cells capable of detecting the loss of HLA-
B. Indeed, KIR3DL1*001 and KIR3DS1, which show high levels of
expression frequency are both protective against HIV-1, and
KIR3DS1 also shows protection against hepatitis C virus [44].
Theoretically, an improved NK sensing of HLA-loss through a
greater number of NK cells expressing the appropriate sensors
would enhance the ability of the individual to detect and eliminate
virally infected cells that have decreased/altered HLA class I
expression. Thus, it will be of much interest to determine the
potential influence of these functionally-significant promoter
variants on HIV disease as well as other human diseases.
Materials and Methods
Donors
Healthy volunteers were recruited through the NCI-Frederick
Research Donor Program (http://www.ncifcrf.gov/rdp/). The
KIR genotype of each donor was determined as previously
described [45].
Antibodies and Cell Lines
The monoclonal antibodies (mAb) used in this study were: PE-
conjugated anti-CD158a/h (KIR2DL1/S1, EB6, IgG1); anti-
CD158b1/b2/j (KIR2DL2/2DL3/2DS2, GL183, IgG1); anti-
CD158e1/e2 (KIR3DL1/S1, ZIN276, IgG1); anti-CD158e1
(KIR3DL1, DX9, IgG1); anti-CD158i (KIR2DS4, FES172,
IgG2a); FITC-conjugated anti-CD3 (IgG1, UCHT1); APC or
PC5-conjugated anti-CD56 (IgG1, NKH.1) (Beckman Coulter
Inc, Miami, FL); PE-Alexa Fluor 700-conjugated anti-CD3 (S4.1,
IgG2a) (Invitrogen Caltag, Carlsbad, CA). The anti-CD158b2
(KIR2DL3, ECM41, IgM) [46] was kindly provided by Dr D.
Mavilio, NIAID, Bethesda, USA. FITC-labeled goat IgG fraction
to mouse IgM was purchased from MP Biomedical (Solon, OH).
Appropriately labeled mouse isotype control mAb were purchased
from the respective companies. YT-Indy cells were cultured in
RPMI 1640 media containing 10% fetal bovine serum, L-
Glutamine, and 100 U/ml each of penicillin and streptomycin.
Flow Cytometric Analysis of KIR Expression on Peripheral
Blood NK Cells
The proportion of NK cells expressing a particular KIR
receptor was assessed in whole blood by three- or four-color flow
cytometry. Briefly, 100 ml of EDTA-treated blood was incubated
with the appropriate cocktail of mAbs. Erythrocytes were lysed
with an ammonium chloride solution and the remaining cells were
analyzed with a FACSort flow cytometer (Becton & Dickinson,
San Jose, CA). Events (25,000) were collected in the lymphocyte
gate and analyzed. NK cells were defined as CD3
2CD56
+
lymphocytes. KIR3DS1 expression on NK cells was investigated
by using DX9 and ZIN276 (Z27) mAbs as previously described
[37]. KIR2DL3 expression on NK cells was obtained by using
GL183 and ECM41 mAbs. Results were expressed as percentages
of NK cells positive for one given KIR receptor.
Generation of Luciferase Reporter Plasmids
Promoter fragments were generated by PCR using a gene-
specific forward primer starting at 2229 and a reverse primer
starting at 21 relative to the start codon of the gene. PCR
products were cloned into the TOPO-TA vector (Invitrogen,
Carlsbad, CA, USA), and inserts were excised with either SacI/
XhoI or XhoI/HindIII and cloned into pGL3 (Promega, Madison,
WI, USA) to generate constructs in both forward and reverse
orientations. All constructs were verified by sequencing with
specific primers. Sequence analysis was performed with the
SeqWeb package at the NCI- Frederick supercomputing center.
Cell Transfection and Luciferase Assays
YT-Indy cells were transfected by electroporation with a BTX
ECM 830 (Gentronics, San Diego, CA, USA) set at 250 mV, with
3 pulses of 7 ms at an interval of 100 ms. A total of 5610
6 cells in
0.5 ml of serum free RPMI medium were transfected with 10 mg
of the specific reporter construct plus 0.1 mg of the Renilla
luciferase pRL-SV40 vector. Luciferase activity was assayed at
48 hr using the Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions. The luciferase
activity of the KIR3DL1 promoter constructs was normalized
relative to the activity of the Renilla luciferase produced by the
pRL-SV40 control vector and each construct was tested in at least
three independent experiments.
Quantitation of KIR3DL1 Antisense Transcripts
Total cellular RNA was isolated from peripheral blood mononu-
clear cells with the RNAqueous-4PCR Kit (Applied Biosystems/
Ambion, Austin, TX), and further purified using DNase I according
to the manufacturer’s instructions. cDNA synthesis was carried out at
55uCu s i n gO l i g o ( d T ) 18 or KIR3DL1/S1-specific- TGGTTTAT-
T(A)GTCACAATTG-39 RT primers with the Transcriptor First
Strand cDNA Synthesis Kit (Roche, Indianapolis, IN). Taqman real
time RT-PCR primers and probes for target genes were: KIR3DL1
antisense transcript Fwd- ATTGTCACAATTGCTCTGAAAACC
-39; Rev- CATGGCTTCCTGGAAATTGCT -39 and probe:
59(FAM)-CATGTTAGCACAGATTTTAGGCATCTCGTG -
(MGB)39. NKp46 Fwd- GGCTGTGTCTGAGTCAGAG -39;
Rev- GAGTTCATGTCCGGGATGTAG -39 and probe 59(VIC)-
CATCTGGGCCGAGCCCCATTTCATG -(MGB)39.T h eP C R
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cDNA, 16Master Mix (TaqMan Universal PCR Master Mix, ABI,
CA), 500 nM of each primer and 100 nM of each probe,
respectively. The thermal cycling conditions were 40 cycles of PCR
amplification (UNG incubation: 50uC, 2 min; AmpliTaqGold
activation: 95uC, 10 min; denaturation: 95uC, 15 s; annealing/
extension: 60uC, 1 min) (7500 Fast Real-Time PCR System, Applied
Biosystems, Foster City, CA). All assays were performed on the same
plate in triplicate. Triplicate Ct values were analyzed using the
comparative Ct (DDCt) method as described by the manufacturer
(Applied Biosystems, Foster City, CA, USA). The relative amount of
KIR3DL1 antisense transcript (2
2DDCt) was obtained by normaliza-
tion to NKp46 and relative to the level of YT-Indy.
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared from YT-Indy cells using the
CellLytic NuCLEAR extraction kit (Sigma-Aldrich, St. Louis,
MO). Protein concentration was measured with a Bio-Rad protein
assay (Hercules, CA) and samples were stored at 270uC until use.
All buffers contained a protease inhibitor cocktail (2 mM 4-(2-
aminoethyl) benzenesulfonylfluoride, 1.4 pM trans-epoxysuccinyl-
l-leucylamido [4-guanidinobutane], 130 pM bestatin, 1 mM leu-
peptin, and 0.3 pM aprotinin; Sigma-Aldrich). Eight double-
stranded DNA oligonucleotide probes corresponding to the
predicted Sp1-binding sequence of the KIR promoter alleles were
synthesized (Figure 3A, sense strand shown). Sense and anti-sense
oligonucleotides were annealed to generate the double-stranded
oligonucleotides and labeled with [a-
32P]dCTP (3000 Ci/mmol;
Perkin Elmer, Waltham, MA) by fill-in using the Klenow fragment
of DNA polymerase I (Invitrogen, Carlsbad, CA). Radio-labeled
double-stranded oligonucleotides were purified using mini Quick
Spin Oligo Columns (Roche, GmbH, Mannheim, Germany).
DNA-protein binding reactions were performed in a 10 ml mixture
containing 10 mg of nuclear protein and 1 mg of poly(dI-
dC)poly(dI-dC) (Sigma-Aldrich) in 4% glycerol, 1 mM MgCl2,
0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCl
(pH 7.5). After a 10-min incubation on ice, samples were
incubated with 1 ml
32P-labeled oligonucleotide probe
(20,000 cpm) at room temperature for 20 min, and then loaded
on a 5% polyacrylamide gel (37:5:1). Electrophoresis was
performed in 0.56TBE buffer for 2 hours at 130 V and the gel
was visualized by autoradiography after 2 days exposure at
270uC. For antibody supershift experiments, nuclear extracts
were incubated with 2 ml of anti-Sp1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) for 1 h on ice prior to the
addition of
32P- labeled DNA probe. After addition of labeled
DNA-probe, the binding reaction was incubated for additional
20 min at room temperature. The human Sp1 recombinant
protein (rhSP1, Promega, Madison, WI) was used as control. For
competition analyses, unlabeled-competitor probe (Sp1 consensus)
and AP2 probes were included in the binding reaction.
Statistical Analysis
Statistical analysis of allele expression frequencies was per-
formed using GraphPad Prism software. Comparison of distribu-
tions was performed using a Mann-Whitney U test. The
correlations between the level of KIR3DL1 antisense transcript
and the frequency of NK cells expressing a given allele were
assessed by Spearman’s correlation coefficient. All p values
reported were two-tailed, with significance defined as p,0.05.
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